Dosing & Uses
Dosage Forms & Strengths
Not indicated for initial therapy
Dosage must be determined by individual titration
Usual: propranolol 40 mg/hydrochlorothiazide 25 mg PO q12hr
For total daily propranolol doses >160 mg, combination is not appropriate; use would lead to excessive thiazide dose
Use caution in dosing/titrating patients with renal dysfunction
Cumulative effects of thiazides may develop with impaired renal function; dose adjustment may be necessary; azotemia may be precipitated
Dose adjustment necessary in severe impairment; specific dosing recomendations not studied
Combination may be substituted for the titrated individual components
Withdraw gradually over a period of about 2 weeks
When necessary, another antihypertensive agent may be added gradually beginning with 50 percent of the usual recommended starting dose to avoid an excessive fall in blood pressure
<18 years: Safety/efficacy not established
Dose reduction may be necessary depending on patient's renal function
Serious - Use Alternative
Significant - Monitor Closely
No adverse effects specific to the combination have been observed; adverse effects limited to those previously reported with propranolol and hydrochlorothiazide
Frequency Not Defined
- Increased AV conduction disturbance
- Congestive heart failure
- Cardiogenic shock
- Psychotic disorder
- Epigastric distress
- Orthostatic hypotension
- Erythema multiforme
- Stevens-Johnson syndrome
- Exfoliative dermatitis including toxic epidermal necrolysis
Black Box Warnings
Beta-blockers may exacerbate ischemic heart disease following abrupt withdrawal
Hypersensitivity to catecholamines has been observed during withdrawal
Exacerbation of angina and, in some cases, myocardial infarction occurrence after abrupt discontinuation
When discontinuing chronically administered beta-blockers (particularly with ischemic heart disease) gradually reduce dose over 1-2 weeks and carefully monitor; if angina markedly worsens or acute coronary insufficiency develops, reinstate beta-blocker administration promptly, at least temporarily (in addition to other measures appropriate for unstable angina)
Warn patients against interruption or discontinuation of beta-blocker without physician advice
Because coronary artery disease is common and may be unrecognized, slowly discontinue beta-blocker therapy, even in patients treated only for hypertension
CHF, unless secondary to tachyarrhythmia treatable with propranolol
Heart block 2°/3°
Hypersensitivity to either component or sulfonamides
Overt cardiac failure
Sinus bradycardia, sick sinus syndrome (unless permanent pacemaker in place)
Anesthesia/surgery (myocardial depression); chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery, however the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures
Acute transient myopia and acute angle-closure glaucoma has been reported, particularly with history of sulfonamide or penicillin allergy (hydrochlorothiazide is a sulfonamide)
Avoid abrupt withdrawal
Diabetes mellitus, fluid or electrolyte imbalance, hyperuricemia or gout, SLE
Hyperthyroidism or thyrotoxicosis, liver disease
May aggravate digitalis toxicity
Peripheral vascular disease
Risk of male sexual dysfunction
Sensitivity reactions may occur with or without history of allergy or asthma
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excreted in breast milk, use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Propranolol hydrochloride/hydrochlorothiazide is a fixed-combination tablet that combines a Beta adrenergic receptor blocker, propranolol hydrochloride, and a thiazide diuretic, hydrochlorothiazide
Propranolol hydrochloride is a nonselective beta-blocker that reduces chronotropic, inotropic and vasodilator responses to beta-adrenergic stimulation by competing for available binding sites that stimulate the beta-adrenergic receptors. The drug controls hypertension through incompletely understood mechanisms
Hydrochlorothiazide is a thiazide diuretic that inhibits Na reabsorption in distal renal tubules resulting in increased excretion of Na+ and water, also K+ and H+ ions
- Half-Life: 1.1-9.9 hr
- Bioavailability: 30-70%
- Onset: 1-2 hr (Beta blockade); 2-3 wk (hypertension)
- Duration: 6 hr
- Vd: 6 L/kg
- Peak plasma time: 2 hr
- Protein bound: 93%
- Metabolism: Liver (P450 enzyme CYP2D6, first-pass metabolism)
- Excretion: Urine (40%); feces (55-60%)
- Dialyzable: No
- Half-Life: 6-15 hr
- Bioavailability: 70%
- Onset: 2 hr (diuresis); 4-6 hr (peak effect)
- Duration: 6-12 hr (diuresis); 1 wk (HTN)
- Vd: 3.6-7.8 L/kg
- Peak Plasma:1.5-2.5 hr
- Protein Bound: 68%
- Metabolism: Minimally metabolized
- Clearance: 335 mL/min
- Excretion: Urine 50-70%
- Dialyzable: No
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.